Risk factor
Low price volatility
Profitability factor
Solid dividends
About
BB Biotech AG is an investment fund overseen by Bellevue Asset Management AG. This fund allocates capital to publicly traded companies worldwide, with a primary focus on firms pioneering modern biotechnology, specifically in the development of medications and diagnostic tools. The construction of its investment portfolio is guided by a fundamental analysis approach. Established on November 9, 1993, BB Biotech AG is headquartered in Switzerland.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is reasonably priced on P/E, 'cheap' on EV/EBITDA, tradin
Target Price
The average target price of BION.SW is 73.0 and suggests 46% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc